The compound (R)-2-((tert-butoxycarbonyl)amino)-2-phenylacetic acid is handled as a protected chiral amino acid building block in peptide synthesis and chiral intermediate manufacturing. In Boc-strategy solid-phase peptide synthesis, Boc-D-phenylglycine is used to insert a D-aryl glycine residue at the N-terminus or at internal positions where sequence design requires a non-proteinogenic residue. The free carboxylic acid is activated in situ with 2.0–2.5 equiv of HATU relative to free amino groups and 4.0–5.0 equiv of DIEA in N,N-dimethylformamide at 0.25–0.50 M. Coupling on 4-methylbenzhydrylamine resin with substitution in the 0.3–1.0 mmol g⁻¹ range is commonly run at 20–25 °C for 45–120 min. The benzylic α-carbon of D-phenylglycine creates measurable steric retardation during acylation, so a positive Kaiser test following the first coupling cycle is managed by a second coupling with 1.5 equiv of the protected amino acid rather than by prolonging the first reaction beyond 120 min. The resin is washed with alternating DMF and dichloromethane after coupling, and N-terminal Boc removal is performed with 30–50% v/v trifluoroacetic acid in dichloromethane containing 2–5% water and 2–5% triisopropylsilane as cation scavenger. Two short deprotection pulses of 2–5 min are preferred to a single long exposure because the arylglycine residue can generate benzylic cations under anhydrous acid conditions. After deprotection, the resin-bound amine is neutralised with 5% DIEA in dichloromethane before the next coupling. Final cleavage from phenylacetamidomethyl resin is carried out with hydrofluoric acid-based cocktails or trifluoromethanesulfonic acid-based cocktails depending on side-chain protection; the presence of the D-aryl glycine residue requires strict temperature control near 0 °C and the inclusion of anisole or thioanisole to suppress alkylation of the aromatic ring. Downstream purification of the crude peptide is monitored by C18 reversed-phase HPLC with UV detection at 210–220 nm, where the phenylglycine chromophore contributes weak absorbance.

What Coupling Conditions Minimise Epimerisation in Solution-Phase Fragment Assembly?

Solution-phase fragment assembly subjects the benzylic α-carbon of Boc-D-phenylglycine to a higher racemization risk than standard aliphatic amino acids because activation of the carboxylic acid can produce an oxazolone intermediate. The preferred activation protocol uses isobutyl chloroformate and N-methylmorpholine in tetrahydrofuran or dichloromethane at -20 to -15 °C for 10–20 min, followed by addition of the amine fragment at -15 to 0 °C. Under these mixed-anhydride conditions, the Boc group still provides N-protection while the low temperature slows oxazolone formation. An alternative carbodiimide method uses 1.0–1.2 equiv of N,N′-diisopropylcarbodiimide or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide with 1.0–1.2 equiv of HOBt in dichloromethane or DMF at 0–5 °C. The carbodiimide route is less tolerant of trace water, and dicyclohexylurea precipitation can complicate downstream filtration at 0 °C. When the target fragment is a short peptide with a free C-terminal ester, the coupling is conducted under a nitrogen blanket and the reaction progress is followed by TLC or LC-MS until the protected starting acid is below 1% area. The resulting peptide bond is generally formed with retention of configuration when HOBt is present, but the exact optical purity of the isolated fragment requires confirmation by chiral HPLC because partial loss of configuration at the α-carbon is not reliably detected by reversed-phase HPLC alone. Table 1 summarises representative process settings for the solid-phase and solution-phase routes used to incorporate Boc-D-phenylglycine into peptide chains.

Chiral Purity as a Release Criterion for D-Phg-Containing Intermediates

A release specification for Boc-D-phenylglycine used in downstream peptide API manufacturing is built around enantiomeric purity, residual solvents, water content, and sulphated ash. The enantiomeric purity is commonly assessed on an amylose tris(3,5-dimethylphenylcarbamate) chiral stationary phase with a mobile phase composed of n-hexane, 2-propanol, and 0.1% trifluoroacetic acid. UV detection is set at 254 nm, and the column is maintained at 25 °C. System suitability typically requires enantiomeric resolution of not less than 1.5 between the L- and D-enantiomers, with the early-eluting L-isomer separated from the main D-isomer by not less than 2 min under isocratic conditions. Because the substance is a protected amino acid rather than a finished drug substance, the exact acceptance limit for the L-enantiomer is set by the end user’s drug master file and the stage of manufacturing. The limit is normally controlled at or below 1.0% area for advanced intermediates, with stricter limits applied when the D-Phg residue is part of a macrocyclic or lantibiotic-like structure where the stereochemical error cannot be removed by crystallisation. Residual solvent testing by headspace gas chromatography follows USP ⟨467⟩, with method variables adjusted according to the solvent class used in the final crystallisation. Water content is determined by Karl Fischer titration according to USP ⟨921⟩, and loss on drying may be used for routine release when the moisture specification is not tighter than 0.5%. Sulphated ash is measured according to USP ⟨281⟩. The analytical test matrix in Table 2 lists the quality attributes and the corresponding compendial references that are commonly cited when the material is qualified as a chemical intermediate for peptide synthesis.

For peptidomimetic work, the protected D-aryl glycine residue is introduced into short-chain analogues that replace a native L-amino acid at a scissile or substrate-recognition position. The absence of the L-configuration at the benzylic carbon reduces recognition by endogenous peptidases, which is a useful design feature when the target molecule must survive short residence times in plasma or intestinal fluid. Boc-D-phenylglycine is coupled to C-terminal amide or ester fragments under the same low-temperature solution-phase conditions used for peptide bond formation. The Boc group remains in place through catalytic hydrogenation of benzyl ester protecting groups, whereas saponification of methyl or ethyl esters is performed with lithium hydroxide at 0–5 °C to avoid premature loss of the acid-labile carbamate. The resulting N-Boc protected peptidomimetic can be deprotected with trifluoroacetic acid in dichloromethane at 0–20 °C for 15–30 min, but the free benzylic amine should not be stored in solution for extended periods because oxidation and imine formation are observed in the presence of ketone solvents. Published data for this specific configuration in protease inhibitor scaffolds is limited compared with phenylalanine-derived building blocks, so process fit is evaluated case by case rather than assumed from aliphatic amino acid analogues.

When a D-Arylglycine Residue Is Required in a Macrocyclic Scaffold

When the target sequence includes a D-arylglycine residue in a macrocyclic scaffold, the building block is usually incorporated before the ring-closing step rather than after cycle formation. The constrained geometry of the benzylic side chain influences the backbone dihedral angles, which can change the product distribution of an on-resin or solution-phase macrocyclisation. In Boc-strategy SPPS, the D-Phg-containing linear precursor is assembled on a 2-chlorotrityl or oxime resin when the macrocycle is to be closed off-resin via a C-terminal activation step. The carboxylic acid is activated with HATU and DIEA in DMF at 0–5 °C, and the dilute cyclisation is typically performed at 1–10 mM peptide concentration to suppress oligomerisation. The phenylglycine residue is monitored by analytical HPLC for benzylic side-chain alteration during the cyclisation step; when the reaction is run above 20 °C in the presence of tertiary amine bases, a measurable increase in late-eluting aromatic impurities can occur. For glycopeptide-like sequences that contain multiple aryl glycine residues, the use of Boc-D-phenylglycine allows selective N-terminal deprotection with TFA while acid-labile side-chain protecting groups remain intact if the protecting scheme is designed around differential acid sensitivity. Ring closure is then attempted with the N-terminal amine unmasked and the C-terminal ester or amide activated as a pentafluorophenyl ester or a 7-azabenzotriazolyl ester. The resulting macrocycle is characterised by high-resolution mass spectrometry and offline chiral amino acid analysis to confirm that the D-Phg residue has not epimerised during ring formation.

Kilogram-scale charging of a protected amino acid such as Boc-D-phenylglycine in a peptide CDMO setting begins with moisture control and reactor atmosphere verification. The material is typically received as a crystalline solid with a molecular weight of 251.28 g mol⁻¹ and should be stored in sealed containers under nitrogen or argon at 2–8 °C. Before use, the solid is equilibrated to room temperature inside a glove bag or a low-humidity dispensing booth to avoid condensation on the crystal surfaces. When Karl Fischer analysis indicates water content above 0.5%, vacuum drying at 25–30 °C under 1–5 kPa for 4–8 h is performed, but the temperature is not increased above 35 °C to avoid premature Boc cleavage. Charging into a glass-lined or stainless-steel reactor is carried out under a nitrogen sweep, and the feed port is flushed with dry dichloromethane or DMF. Dissolution in DMF at 0.25–0.50 M is usually complete within 15–30 min under moderate agitation. The resulting solution is transferred through an in-line filter to remove undissolved mechanical particles before coupling. When the building block is used in a multi-kilogram campaign, batch-to-batch variability in particle size can affect dissolution time but not stereochemical purity if the material is supplied as a single lot. Analytical release data are reviewed against the customer’s approved specification before reactor charging, and any lot with an L-enantiomer result above the agreed threshold is quarantined for physical rework or returned to the supplier.